Literature DB >> 9710888

Soluble tumor necrosis factor receptor (p75) fusion protein (ENBREL) as a therapy for rheumatoid arthritis.

L W Moreland1.   

Abstract

Soluble tumor necrosis factor (TNF) receptor fusion protein (p75) (Enbrel) is a reversible inhibitor of the biologic effects of TNF. Enbrel has been shown in placebo-controlled trials to significantly improve the signs and symptoms of rheumatoid arthritis. Clinical trials are now in progress to assess the safety and efficacy of Enbrel in combination with methotrexate in refractory rheumatoid arthritis along with trials to compare Enbrel to methotrexate in patients with early rheumatoid arthritis.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9710888     DOI： 10.1016/s0889-857x(05)70027-2

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN： 0889-857X            Impact factor:   2.670


  14 in total

Review 1.  Access to disease modifying treatments for rheumatoid arthritis patients.

Authors:  D E Furst; F C Breedveld; G R Burmester; L Crofford; P Emery; M Feldman; J R Kalden; A Kavanaugh; E Keystone; P E Lipsky; R N Maini; L Moreland; J S Smolen; L Van De Putte; T Vischer; M Weinblatt; M Weissman
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  Engineering a genetically encoded competitive inhibitor of the KEAP1-NRF2 interaction via structure-based design and phage display.

Authors:  Gurkan Guntas; Steven M Lewis; Kathleen M Mulvaney; Erica W Cloer; Ashutosh Tripathy; Thomas R Lane; Michael B Major; Brian Kuhlman
Journal:  Protein Eng Des Sel       Date:  2015-10-20       Impact factor: 1.650

3.  NO-naproxen modulates inflammation, nociception and downregulates T cell response in rat Freund's adjuvant arthritis.

Authors:  C Cicala; A Ianaro; S Fiorucci; A Calignano; M Bucci; R Gerli; L Santucci; J L Wallace; G Cirino
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

Review 4.  Progress in the use of biochemical and biological markers for evaluation of rheumatoid arthritis.

Authors:  R M Nakamura
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

5.  Methyl salicylate lactoside inhibits inflammatory response of fibroblast-like synoviocytes and joint destruction in collagen-induced arthritis in mice.

Authors:  Wenyu Xin; Chao Huang; Xue Zhang; Sheng Xin; Yiming Zhou; Xiaowei Ma; Dan Zhang; Yongjie Li; Sibai Zhou; Dongming Zhang; Tiantai Zhang; Guanhua Du
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

Review 6.  Use of biologics in the treatment of childhood rheumatic diseases.

Authors:  T Arkachaisri; T J Lehman
Journal:  Curr Rheumatol Rep       Date:  2000-08       Impact factor: 4.592

7.  Virus-induced transient immune suppression and the inhibition of T cell proliferation by type I interferon.

Authors:  Heather D Marshall; Stina L Urban; Raymond M Welsh
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

8.  Efficacy and Safety of Opinercept Tumor Necrosis Factor Inhibitor Therapy for Drug-Refractory Rheumatoid Arthritis: A Randomized Clinical Trial.

Authors:  Toong-Hua Liang; Chyou-Shen Lee; Shinn-Shing Lee; Chien-Sheng Wu; Kun-Hung Chen; Ping-Ning Hsu; Hsiao-Yi Lin
Journal:  Arch Rheumatol       Date:  2020-01-08       Impact factor: 1.472

Review 9.  Nerve growth factor (NGF) and NGF receptors in mesenchymal stem/stromal cells: Impact on potential therapies.

Authors:  Kangkang Zha; Yu Yang; Guangzhao Tian; Zhiqiang Sun; Zhen Yang; Xu Li; Xiang Sui; Shuyun Liu; Jinmin Zhao; Quanyi Guo
Journal:  Stem Cells Transl Med       Date:  2021-02-15       Impact factor: 6.940

10.  Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson's Disease?

Authors:  María C Leal; Juan C Casabona; Mariana Puntel; Fernando J Pitossi
Journal:  Front Cell Neurosci       Date:  2013-04-29       Impact factor: 5.505
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.